Literature DB >> 36036323

National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs).

Eva Rath1,2, Michael Bonelli1,3, Christina Duftner1,4, Johann Gruber1,4, Peter Mandl1,3, Florentine Moazedi-Furst1,5, Herwig Pieringer1,6, Rudolf Puchner1,7, Holger Flick8,9, Helmut J F Salzer8,10, Günter Weiss1,11,4, Stefan Winkler11,12, Hans Skvara13,14, Alexander Moschen15,16, Harald Hofer15,17, Julia Feurstein1,2, Judith Sautner18,19,20.   

Abstract

This publication provides a thorough analysis of the most relevant topics concerning the management of latent tuberculosis when using biologic and targeted synthetic Disease Modifying Antirheumatic Drugs (DMARDs) by a multidisciplinary, select committee of Austrian physicians. The committee includes members of the Austrian Societies for Rheumatology and Rehabilitation, Pulmonology, Infectiology, Dermatology and Gastroenterology. Consensus was reached on issues regarding screening and treatment of latent tuberculosis and includes separate recommendations for each biologic and targeted synthetic DMARD.
© 2022. The Author(s).

Entities:  

Keywords:  Antibiotic regimen; Biologic and targeted synthetic DMARDs; Incidence; Latent tuberculosis; Tuberculosis

Year:  2022        PMID： 36036323     DOI： 10.1007/s00508-022-02062-7

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN： 0043-5325            Impact factor:   2.275


  28 in total

1.  Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years.

Authors:  Ronald F van Vollenhoven; Roy M Fleischmann; Daniel E Furst; Stuart Lacey; Patricia B Lehane
Journal:  J Rheumatol       Date:  2015-08-15       Impact factor: 4.666

Review 2.  Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice.

Authors:  Fabrizio Cantini; Laura Niccoli; Alessandro Capone; Linda Petrone; Delia Goletti
Journal:  Expert Opin Drug Saf       Date:  2019-05-08       Impact factor: 4.250

Review 3.  Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.

Authors:  Silvia Minozzi; Stefanos Bonovas; Theodore Lytras; Valentina Pecoraro; Marien González-Lorenzo; Anan Judina Bastiampillai; Eugenia Maria Gabrielli; Andrea Carlo Lonati; Lorenzo Moja; Michela Cinquini; Valentina Marino; Andrea Matucci; Giuseppe Maria Milano; Giuliano Tocci; Raffaele Scarpa; Delia Goletti; Fabrizio Cantini
Journal:  Expert Opin Drug Saf       Date:  2016-12       Impact factor: 4.250

Review 4.  Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease.

Authors:  Luca Cantarini; Giuseppe Lopalco; Francesco Caso; Luisa Costa; Florenzo Iannone; Giovanni Lapadula; Maria Grazia Anelli; Rossella Franceschini; Cristina Menicacci; Mauro Galeazzi; Carlo Selmi; Donato Rigante
Journal:  Autoimmun Rev       Date:  2014-08-22       Impact factor: 9.754

5.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Authors:  J Keane; S Gershon; R P Wise; E Mirabile-Levens; J Kasznica; W D Schwieterman; J N Siegel; M M Braun
Journal:  N Engl J Med       Date:  2001-10-11       Impact factor: 91.245

Review 6.  ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52).

Authors:  M Mikulska; S Lanini; C Gudiol; L Drgona; G Ippolito; M Fernández-Ruiz; B Salzberger
Journal:  Clin Microbiol Infect       Date:  2018-02-12       Impact factor: 8.067

Review 7.  ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).

Authors:  K L Winthrop; X Mariette; J T Silva; E Benamu; L H Calabrese; A Dumusc; J S Smolen; J M Aguado; M Fernández-Ruiz
Journal:  Clin Microbiol Infect       Date:  2018-02-12       Impact factor: 8.067

Review 8.  Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice.

Authors:  Fabrizio Cantini; Carlotta Nannini; Laura Niccoli; Florenzo Iannone; Giovanni Delogu; Giacomo Garlaschi; Alessandro Sanduzzi; Andrea Matucci; Francesca Prignano; Michele Conversano; Delia Goletti
Journal:  Autoimmun Rev       Date:  2015-01-21       Impact factor: 9.754

Review 9.  ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).

Authors:  J W Baddley; F Cantini; D Goletti; J J Gómez-Reino; E Mylonakis; R San-Juan; M Fernández-Ruiz; J Torre-Cisneros
Journal:  Clin Microbiol Infect       Date:  2018-02-06       Impact factor: 8.067

10.  The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).

Authors:  K Reich; M Gooderham; L Green; A Bewley; Z Zhang; I Khanskaya; R M Day; J Goncalves; K Shah; V Piguet; J Soung
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-12-19       Impact factor: 6.166
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.